CRISPR Therapeutics (NASDAQ:CRSP) and MaxCyte today announced the expansion of their existing relationship by entering into a non-exclusive commercial license agreement that will allow CRISPR Therapeutics to deploy MaxCyte’s Flow Electroporation® Technology to develop CRISPR/Cas9-based therapies in immuno-oncology.
{iframe}https://www.maxcyte.com/crispr-therapeutics-and-maxcyte-expand-clinical-and-commercial-license-agreement-into-oncology/{/iframe}